1994
DOI: 10.1378/chest.105.3.806
|View full text |Cite
|
Sign up to set email alerts
|

Macrophage Activation by N-Acetyl-cysteine in COPD Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
20
0
1

Year Published

1998
1998
2018
2018

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 29 publications
(21 citation statements)
references
References 32 publications
0
20
0
1
Order By: Relevance
“…This reduction in oxidative biomarkers results in clinical benefit, such as reduction in bronchial hypersecretion [187], in addition to a decline in FEV1 and in exacerbations [178]. Orally dosed NAC has been shown to increase phagocytic activity of BAL macrophages from healthy smokers [188], but similar results were not seen in COPD patients, possibly due to active concentrations of NAC not reaching the lung [189]. It has also been reported recently that orally dosed NAC increased the quadricep endurance time of severe COPD patients [190], thus suggesting that NAC administration may have beneficial effects on the systemic oxidative stress associated with COPD.…”
Section: N-acetyl-l-cysteinementioning
confidence: 99%
“…This reduction in oxidative biomarkers results in clinical benefit, such as reduction in bronchial hypersecretion [187], in addition to a decline in FEV1 and in exacerbations [178]. Orally dosed NAC has been shown to increase phagocytic activity of BAL macrophages from healthy smokers [188], but similar results were not seen in COPD patients, possibly due to active concentrations of NAC not reaching the lung [189]. It has also been reported recently that orally dosed NAC increased the quadricep endurance time of severe COPD patients [190], thus suggesting that NAC administration may have beneficial effects on the systemic oxidative stress associated with COPD.…”
Section: N-acetyl-l-cysteinementioning
confidence: 99%
“…A study in Switzerland suggested that therapy with N-acetylcysteine was cost effective (363). The mechanism by which N-acetylcysteine reduces AECB is unclear but may be related to enhancing macrophage activity, which would help defend against mucosal infections (364). N-acetylcysteine therapy should be considered in patients with more than five exacerbations per year (Level I evidence).…”
Section: Prevention Of Aecbmentioning
confidence: 99%
“…NAC treatment significantly enhanced antifungal activity of peripheral blood monocytes (PBM) from these patients. Long-term NAC treatment could augment resistance against microbial infections, which are often life-threatening in these patients [84].…”
Section: N-acetyl Cysteine (Nac)mentioning
confidence: 99%